Unresolved issues of antibiotic therapy of infections caused by Staphylococcus aureus

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(3):189-195

​ Popov D.A.
10.36488/cmac.2020.3.189-195
Staphylococcus aureus antibiotic therapy ceftaroline biofilms bloodstream infections
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(3):189-195

Abstract

Staphylococcal infections are widespread among outpatients and hospitalized patients. Despite the apparent diversity of the “menu” of anti-staphylococcal drugs, treatment results in several patients are not good as expected. This is due to the properties of pathogens exhibiting various mechanisms of antimicrobial resistance, including biofilm formation, limited penetration of the drug into the focus of infection, which is largely dependent on its location, as well as basic characteristics of antimicrobial agent (activity, ability to achieve bactericidal concentrations in infectious foci, and toxicity). This review provides up-to-date information on the ways to improve treatment of patients with infections caused by Staphylococcus aureus.

Dmitriy A. Popov

A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russia

  • 1. Rasigade J.P., Vandenesch F. Staphylococcus aureus: a pathogen with still unresolved issues. Infect Genet Evol. 2014;21:510– 514. DOI: 10.1016/j.meegid.2013.08.018
  • 2. Nikulin A.A., Dekhnich A.V. Overview of British Guidelines on the Management of CA-MRSA Infections. Clinical microbiology and antimicrobial chemotherapy. 2010;12(1):4-22. Russian.
  • 3. Dai Y., Liu J., Guo W., Meng H., Huang Q., He L., et al. Decreasing methicillin-resistant Staphylococcus aureus (MRSA) infections is attributable to the disappearance of predominant MRSA ST239 clones, Shanghai, 20082017. Emerg Microbes Infect. 2019;8(1):471-478. DOI: 10.1080/22221751.2019.1595161
  • 4. Sukhorukova М.V., Skleenova Е. Yu., Ivanchik N.V., TimokhovaА.V., Edelstein М.V., Dekhnich A.V., et al. Antimicrobial Resistance of Nosocomial Staphylococcus aureus Isolates in Russia: Results of National Multicenter Surveillance Study «MARATHON» 20112012. Clinical microbiology and antimicrobial chemotherapy. 2014;16(4):280-286. Russian.
  • 5. Romanov А.V., Dekhnich А.V., Sukhorukova М.V., Skleenova Е. Yu., Ivanchik N.V., Edelstein М.V., et al. Antimicrobial resistance of nosocomial Staphylococcus aureus isolates in Russia: results of multicenter epidemiological study «MARATHON» 20132014. Clinical microbiology and antimicrobial chemotherapy. 2017;19(1):57-62. Russian.
  • 6. WHO priority pathogens list for R&D of new antibiotics. Available at: www.who.int/news-room/detail/27-02-2017-who-publisheslist-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed May 5, 2020. Russian.
  • 7. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy. 2005;25:7485. DOI: 10.1592/phco.25.1.74.55620
  • 8. de Kraker M.E., Wolkewitz M., Davey P.G., Koller W., Berger J., Nagler J., et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2011;55(4):1598605. DOI: 10.1128/AAC.01157-10
  • 9. Mermel L.A., Allon M., Bouza E., Craven D.E., Flynn P., O'Grady N.P., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45. DOI: 10.1086/599376
  • 10. Gould I.M. VRSA-doomsday superbug or damp squib? Lancet Infect Dis. 2010;10(12):816-818. DOI: 10.1016/S14733099(10)70259-0
  • 11. Soriano A., Marco F., Martínez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200. DOI: 10.1086/524667
  • 12. Stryjewski M.E., Szczech L.A., Benjamin D.K. Jr., Inrig J.K., Kanafani Z.A., Engemann J.J., et al. Use of vancomycin or firstgeneration cephalosporins for the treatment of hemodialysisdependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44(2):190-196. DOI: 10.1086/510386
  • 13. van Hal S.J., Paterson D.L., Lodise T.P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734-744. DOI: 10.1128/AAC.01568-12
  • 14. Khatib R., Johnson L.B., Fakih M.G., Riederer K., Khosrovaneh A., Shamse Tabriz M., et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38(1):7-14. DOI: 10.1080/00365540500372846
  • 15. Morata L., Alejo I., Fernandez I., Cobos-Trigueros N., De la Calle C., Almela M., et al. Predictors of persistent S. aureus bacteraemia and impact in related mortality. ECCMID 2014, Barcelona, Spain, eP098.
  • 16. Popov D.A., Zubareva N.A., Dekhnich A.V. Evidence Based Review on Daptomycin Use in the Treatment of Gram-Positive Infections. Clinical microbiology and antimicrobial chemotherapy. 2016;18(4):270-281. Russian.
  • 17. Dekhnich А.V., Zubareva N.А., Kozlov R.S., Popov D.А., Romanov A.V., Rudnov V.А. Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers. Clinical microbiology and antimicrobial chemotherapy. 2015;17(2):127-145. Russian.
  • 18. Roberts K.D., Sulaiman R.M., Rybak M.J. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of GramPositive Infections. Pharmacotherapy. 2015;35(10):935-948. DOI: 10.1002/phar.1641
  • 19. Corey G.R., Wilcox M.H., Talbot G.H., Thye D., Friedland D., Baculik T. et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;(Suppl. 4):iv41-51. DOI: 10.1093/jac/dkq254
  • 20. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, et.al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl. 4):iv53-iv65. DOI: 10.1093/jac/dkq255
  • 21. File T.M. Jr., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. FOCUS 1: a randomized, double-blinded, multicenter, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii19-32. DOI: 10.1093/jac/dkr096
  • 22. Low D.E., File T.M. Jr., Eckburg P.B., Talbot G.H., David Friedland H., Lee J, et al. FOCUS 2: a randomized, doubleblinded, multicenter, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl. 3):iii3344. DOI: 10.1093/jac/dkr097
  • 23. Golikova M., Dovzhenko S., Kobrin M., Portnoy Y., Zinner S., Firsov A. Comparative pharmacodynamics of ceftaroline and linezolid against Staphylococcus aureus in an in vitro dynamic model. ECCMID 2014, Amsterdam, Netherlands, P1196.
  • 24. Duplessis C., Crum-Cianflone N.F. Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther. 2011;10(3). pii: a2466. DOI: 10.4137/CMRT.S1637
  • 25. Citron D., Tyrrell K., Merriam C., Goldstein E. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother. 2010;54:1627-1632. DOI: 10.1128/AAC.01788-09
  • 26. Rosanova M.T., Aguilar P.S., Sberna N., Lede R. Efficacy and safety of ceftaroline: systematic review and metaanalysis. Ther Adv Infectious Dis. 2019;6:1-13. DOI: 10.1177/2049936118808655
  • 27. Del Pozo JL. Biofilm-related disease. Expert Rev Anti Infect Ther. 2018;16(1):51-65. DOI: 10.1080/14787210.2018.1417036
  • 28. Wang H, Tong H, Liu H, Wang Y, Wang R, Gao H, et al. Effectiveness of antimicrobial-coated central venous catheters for preventing catheter-related blood-stream infections with the implementation of bundles: a systematic review and network metaanalysis. Ann Intensive Care. 2018;8(1):71. DOI: 10.1186/s13613-018-0416-4
  • 29. Parra-Ruiz J., Vidaillac C., Rybak M.J. Macrolides and staphylococcal biofilms. Rev Esp Quimioter. 2012;25(1):10-16. PMID: 22488536
  • 30. Zimmerli W., Sendi P. Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in OrthopedicDevice-Related Infections. Antimicrob Agents Chemother. 2019;63(2). pii: e01746-18. DOI: 10.1128/AAC.01746-18
  • 31. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-3128. DOI: 10.1093/eurheartj/ehv319
  • 32. Cirioni O., Mocchegiani F., Ghiselli R., Silvestri C., Gabrielli E., Marchionni E., et al. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg. 2010;40(6):817-822. DOI: 10.1016/j.ejvs.2010.08.009
  • 33. Chan C., Hardin T.C., Smart J.I. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections. Future Microbiol. 2015;10(8):1325-1338. DOI: 10.2217/fmb.15.53
  • 34. Cafiso V., Bertuccio T., Spina D., Purrello S., Stefani S. Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus: comparison with other drugs. FEMS Immunol Med Microbiol. 2010;59(3):466-469. DOI: 10.1111/j.1574695X.2010.00701.x
  • 35. Mihailescu R., Furustrand Tafin U., Corvec S., Oliva A., Betrisey B., Borens O., et al. High activity of Fosfomycin and Rifampin against methicillin-resistant Staphylococcus aureus biofilm in vitro and in an experimental foreignbody infection model. Antimicrob Agents Chemother. 2014;58(5):2547-2553. DOI: 10.1128/AAC.02420-12
  • 36. Meeker D.G., Beenken K.E., Mills W.B., Loughran A.J., Spencer H.J., Lynn W.B., et al. Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm. Antimicrob Agents Chemother. 2016;60(10):5688-5694. DOI: 10.1128/AAC.01251-16
  • 37. Destache C.J., Guervil D.J., Kaye K.S. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents. 2019;53(5):644-649. DOI: 10.1016/j.ijantimicag.2019.01.014
  • 38. Dhand A., Bayer A.S., Pogliano J., Yang S.J., Bolaris M., Nizet V., et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53(2):158-163. DOI: 10.1093/cid/cir340
  • 39. Geriak M., Haddad F., Rizvi K., Rose W., Kullar R., LaPlante K., et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2019;63(5). pii: e02483-18. DOI: 10.1128/AAC.02483-18
  • 40. Tong S.Y.C., Lye D.C., Yahav D., Sud A., Robinson J.O., Nelson J., et al. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. JAMA. 2020;323(6):527-537. DOI: 10.1001/jama.2020.0103
Views
0 Abstract
0 PDF
0 Crossref citations
Shared